01 Increasing Integration of Smart Insulin Pens with Continuous Glucose Monitoring and Digital Diabetes Platforms Smart insulin pens are increasingly becoming part of connected diabetes management ecosystems that combine dose tracking, mobile applications, glucose monitoring, and digital health platforms. Integration with continuous glucose monitoring data can improve visibility into insulin use, support more informed dosing decisions, and enable patients and healthcare professionals to manage therapy using connected data. In April 2026, industry analysis highlighted stronger integration of smart insulin pens with continuous glucose monitoring and connected diabetes platforms as an important direction for digital insulin management.
02 Growing Adoption of Bluetooth-Enabled and Data-Driven Smart Insulin Pens Bluetooth connectivity, automated dose recording, reminders, and digital dose-history functions are increasing the functionality of smart insulin pens beyond conventional insulin delivery. These features can reduce missed-dose uncertainty, improve treatment adherence, and allow insulin-use information to be shared with caregivers and healthcare professionals for more personalized diabetes management. In August 2026, market analysis identified Bluetooth-connected smart insulin pens as a leading connectivity segment, supported by demand for seamless dose tracking and integration with smartphone-based diabetes management.
01 Rising Diabetes Prevalence and Demand for Connected Insulin Management Support Smart Insulin Pens Market Growth Smart insulin pens provide a connected alternative to conventional injection devices by recording doses, providing reminders, and supporting digital diabetes management, making them increasingly relevant for patients using multiple daily injections.
01 High Costs and Limited Reimbursement Can Restrict Smart Insulin Pen Adoption Smart insulin pens require additional hardware, connectivity features, software platforms, and in some cases compatible digital services that can increase costs compared with conventional insulin pens. Limited reimbursement coverage and differences in healthcare payment structures can make advanced connected devices less accessible to price-sensitive patients and healthcare systems.
01 Expansion of Remote Diabetes Management and Personalized Insulin Therapy Creates New Growth Opportunities Digital dose histories can help clinicians review insulin use outside clinical settings, identify adherence issues, and support more individualized treatment adjustments, expanding the role of smart pens in connected chronic care.
01 Maintaining Interoperability, Data Security, and Reliable Digital Performance Creates Challenges Smart insulin pens increasingly need to interact with smartphones, glucose monitoring systems, diabetes applications, and clinical platforms. Differences in software environments, connectivity standards, cybersecurity requirements, and data formats can complicate integration while reliable dose recording and secure transmission remain essential for safe diabetes management.
March 2026 Novo Nordisk expanded its connected diabetes care portfolio with smart insulin pen technologies designed to improve dose tracking, digital integration, and personalized insulin management for people with diabetes.
January 2026 Eli Lilly expanded its insulin delivery ecosystem with connected insulin pen solutions and digital health integrations aimed at improving medication adherence, glucose management, and patient outcomes.
October 2025 Ypsomed expanded its smart injection device portfolio with advanced connected insulin pen platforms featuring digital dose recording and compatibility with diabetes management applications.
August 2025 Companion Medical (integrated into Medtronic) continued advancements in smart insulin pen technologies through connected insulin delivery solutions designed to support automated dose capture and improved diabetes management workflows.